Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Journal of Clinical Investigation

Volumn 124, Issue 2, 2014, Pages 499-508

  Ferrannini, Ele ^a   Muscelli, Elza ^a   Frascerra, Silvia ^a   Baldi, Simona ^a   Mari, Andrea ^b   Heise, Tim ^c   Broedl, Uli C ^d   Woerle, Hans Juergen ^d  

^a UNIVERSITY OF PISA   (Italy)

^b CNR   (Italy)

^c Profil   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY MASS INDEX; CALORIMETRY; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; GLUCOSIDES; GLYCOSURIA; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; METFORMIN; MIDDLE AGED; OXYGEN; POSTPRANDIAL PERIOD; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84893872877     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72227     Document Type: Article

References (46)

1. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733-794.
2. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 SGLT2. Am J Physiol Cell Physiol. 2011;300(1):C14-C21.
3. Turner JM, Silverman M. Sugar uptake into brush border vesicles from normal human kidney. Proc Natl Acad Sci U S A. 1977;74(7):2825-2829.
4. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79(5):1510-1515.
5. Yki-Järvinen H. Glucose toxicity. Endocr Rev. 1992;13(3):415-31.
6. Vallon V, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22(1):104-112.
7. Jurczak MJ, et al. SGLT2 deletion improves glucose homeostasis preserves pancreatic beta-cell function. Diabetes. 2011;60(3):890-898.
8. Vallon V, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2013;304(2):F156-F167.
9. Calado J, et al. Familial renal glucosuria: SLC5A2 mutation analysis evidence of salt-wasting. Kidney Int. 2006;69(5):852-855.
10. Lee H, et al. Familial renal glucosuria: a clinicogenetic study of 23 additional cases. Pediatr Nephrol. 2012;27(7):1091-1095.
11. Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289-2312.
12. Paisley AJ, Yadav R, Younis N, Rao-Balakrishna P, Soran H. Dapagliflozin: a review on efficacy, clinical effectiveness and safety. Expert Opin Investig Drugs. 2013;22(1):131-140.
13. Devineni D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013;53(6):601-610.
14. Nagata T, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo-or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013;304(4):E414-E423.
15. Tahara A, et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci. 2012;120(1):36-44.
16. Heise T, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613-621.
17. Zambrowicz B, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92(2):158-169.
18. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale clinical prospects. Nat Rev Endocrinol. 2012;8(8):495-502.
19. Muscelli E, et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97(8):2818-2826.
20. Camastra S, et al. Long-term effects of bariatric surgery on meal disposal and β-cell function in diabetic and nondiabetic patients. Diabetes. 2013;62(11):3709-3717.
21. Ferrannini E, et al. Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. Diabetologia. 2011;54(6):1507-1516.
22. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest. 1983;72(5):1737-1747.
23. Gastaldelli A, et al. Influence of obesity and type 2 diabetes on gluconeogenesis glucose output in humans: a quantitative study. Diabetes. 2000;49(8):1367-1373.
24. Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH. Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest. 1984;74(6):2296-2299.
25. Nicolaus M, Brödl J, Linke R, Woerle HJ, Göke B, Schirra J. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, gastric emptying. J Clin Endocrinol Metab. 2011;96(1):229-236.
26. Nilsson O, Bilchik AJ, Goldenring JR, Ballantyne GH, Adrian TE, Modlin IM. Distribution and immunocytochemical colocalization of peptide YY and enteroglucagon in endocrine cells of the rabbit colon. Endocrinology. 1991;129(1):139-148.
27. Habib AM, et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology. 2012;153(7):3054-3065.
28. Habib AM, Richards P, Rogers GJ, Reimann F, Gribble FM. Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells. Diabetologia. 2013;56(6):1413-1416.
29. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes. 2012;61(9):2199-2204.
30. Woerle HJ, et al. Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab. 2006;290(1):E67-E77.
31. Bolinder J, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin [published online ahead of print August 1, 2013]. Diabetes Obes Metab. doi:10.1111/dom.12189.
32. Vasilakou D, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review meta-analysis. Ann Intern Med. 2013;159(4):262-274.
33. Gastaldelli A, et al. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. Clin Pharmacol Ther. 2007;81(2):205-212.
34. Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr. 1980;33(1):27-39.
35. Mari A, Stojanovska L, Proietto J, Thorburn AW. A circulatory model for calculating non-steady-state glucose fluxes. Validation and comparison with compartmental models. Comput Methods Programs Biomed. 2003;71(3):269-281.
36. Natali A, et al. Dose-response characteristics of insulin action on glucose metabolism: a nonsteady-state approach. Am J Physiol Endocrinol Metab. 2000;278(5):E794-E801.
37. Bonuccelli S, et al. Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. Am J Physiol Endocrinol Metab. 2009;297(2):E532-E537.
38. Polidori D, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154-2161.
39. Taylor HL, Tiede K. A comparison of the estimation of the basal cardiac output from a linear formula and the cardiac index. J Clin Invest. 1952;31(2):209-216.
40. Cherrick GR, Stein SW, Leevy CM, Davidson CS. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest. 1960;39:592-600.
41. Fisher M, Sherwin RS, Hendler R, Felig P. Kinetics of glucagon in man: effects of starvation. Proc Natl Acad Sci U S A. 1976;73(5):1735-1739.
42. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism. 1988;37(3):287-301.
43. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of β-cell action: modelling analysis in normal subjects. Am J Physiol Endocrinol Metab. 2002;283(3):E1159- E1166.
44. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992;41(3):368-377.
45. Ferrannini E, et al. The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism. 1988;37(1):79-85.
46. Mari A, Wahren J, DeFronzo RA, Ferrannini E. Glucose absorption and production following oral glucose: comparison of compartmental and arteriovenous-difference methods. Metabolism. 1994;43(11):1419-1425.